Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Contract/Agreement, Product/Service

TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology


TriLink BioTechnologies (TriLink®), a Maravaitm LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries. This agreement with Lonza strengthens TriLink's objective to drive greater access to CleanCap® mRNA capping technologies as the demand for mRNA ? a promising therapeutic modality ? continues to grow.

According to the terms of the agreement, TriLink® will supply its patented CleanCap® M6, CleanCap® AG 3'OMe, CleanCap® AG, and CleanCap® AU cap analogs for use in Lonza's global mRNA development and manufacturing services, from pre-clinical through Phase III programs. CleanCap® technology is a one-pot solution with over 95% capping efficiency that streamlines mRNA production processes when compared to legacy capping methods.

"CleanCap® technology is accelerating programs from discovery to the clinic via improved mRNA function, streamlined manufacturing, and maximized capped material yield," shared Drew Burch, President of Nucleic Acid Production at TriLink. "We're thrilled to offer our innovative capping solutions to Lonza and its customers."

Since its launch in 2017, TriLink's CleanCap® capping technology has continued to advance the mRNA capping industry and is used in a majority of approved mRNA and saRNA vaccines. In May 2023, TriLink introduced its most robust CleanCap analog to date, CleanCap® M6, with studies indicating increased mRNA expression by more than 30% versus enzymatic capping methods.

About TriLink BioTechnologies

TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.

For more information, visit trilinkbiotech.com.

About Maravai LifeSciences

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

For more information about Maravai LifeSciences, visit maravai.com.


These press releases may also interest you

at 19:56
Breakthrough New York Names Next Executive Director Nikki Thompson
Nikki began the role on May 15 and brings an extensive background in the social sector in NYC, with a focus on education. She started her career as an admissions officer at Barnard, then worked as a 7th grade social studies teacher in East New York,...

at 17:55
Broadway Financial Corporation Announces Notification from Nasdaq Regarding Late Filing of Form 10-Q and Form 10-K
Broadway Financial Corporation ("Broadway," "we," or the "Company") , parent company of City First Bank, National Association, announced today it received a Staff Delisting Determination letter (the "Staff Determination") from the Listing...

at 16:35
InfuSystem Announces $20 Million Stock Repurchase Program
InfuSystem Holdings, Inc. ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today that the Company's Board...

at 16:35
Nordson Corporation Reports Second Quarter Fiscal 2024 Results and Updates Annual Guidance
Nordson Corporation today reported results for the fiscal second quarter ended April 30, 2024. Sales were $651 million, comparable to the prior year's second quarter sales of $650 million. The second quarter 2024 sales included a favorable...

at 16:30
SIMPSON MANUFACTURING CO., INC. ANNOUNCES UDIT MEHTA AS CHIEF TECHNOLOGY OFFICER
Simpson Manufacturing Co., Inc. (the "Company") , an industry leader in engineered structural connectors and building solutions, today announced Udit Mehta has joined the Company as Chief Technology Officer, effective May 10, 2024....

at 16:28
Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session
?Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based Background Regimen Alone, As Measured By the QOL-B Respiratory Domain Instrument? ?QOL-B...

More news about Covid-19 virus...


News published on and distributed by: